SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing significant volatility as investors digest the failure of the BlueBird 7 satellite to reach its intended orbit during a Blue Origin mission, though the community remains divided between those bracing for a sharp sell-off and those viewing the dip as a strategic buying opportunity. While the company confirmed insurance will cover the financial loss and reaffirmed its long-term deployment goals, market participants are heavily debating the reliability of launch providers, the impact of project delays, and the company's reliance on external partners for its upcoming constellation buildout.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is currently driving significant community activity due to a low-float setup and speculative hype surrounding a presidential executive order aimed at fast-tracking psychedelic research for veteran mental health. Traders are closely monitoring for a potential short squeeze, though skeptical voices in the community warn of a 'buy-the-rumor' sell-off and potential volatility associated with micro-cap biotech momentum plays.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is seeing significant market focus following the announcement of commercial yttrium metal production at its UK facility and a strategic investment in French processor Carester, bolstering the firm's non-China supply chain narrative. Investors are actively debating the impact of these developments against potential short-term dilution and the broader macro sensitivity of critical mineral stocks to government policy and trade tensions.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is drawing significant attention as investors react to reports of a custom AI chip collaboration with Google, marking a potential shift toward deeper hyperscaler integration. While some community members highlight the stock's recent rapid gains and extended valuation as a sign of caution, bulls remain focused on the company's expanding role in AI infrastructure and custom ASIC production.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is experiencing high volatility as investors react to the sudden resignation of its CEO and a strategic management shakeup, sparking debate over whether the leadership transition will accelerate or hinder the company's ability to secure a major data center tenant. While retail sentiment remains deeply divided between those viewing the price decline as a long-term buying opportunity and those concerned about the company's burn rate and lack of signed contracts, trading volume has surged amid speculation regarding potential partnerships and the company's critical role in AI energy infrastructure.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is seeing significant investor attention driven by speculation surrounding upcoming clinical data readouts and potential partnership or buyout activity in the biotech sector. While bullish sentiment is fueled by anticipation of key oncology data and potential regulatory progress, the community remains divided, with some investors focusing on long-term pipeline potential while others express frustration over share price performance and past dilution.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to the release of positive preliminary data from the open-label arm of its Phase III FLAMINGO-01 trial, which showed a statistically significant reduction in breast cancer recurrence rates. The community is actively discussing the implications of this efficacy, noting the significant endorsement from the trial's global steering committee and high levels of insider investment, fueling optimism for upcoming data presentations at the AACR annual meeting.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Compass Pathways is trending as the community closely monitors a pivotal clinical data readout for its COMP360 psilocybin therapy, amid significant buzz around President Trump's recent executive order to fast-track psychedelic research. Investors are actively debating the company's valuation, its competitive positioning against other biotech players in the space, and the potential impact of new regulatory tailwinds on the sector's long-term commercialization prospects.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is currently trending as investors weigh strong steel shipment guidance for 2026 and optimism surrounding the company's integrated electrical steel capabilities against concerns regarding short-term earnings headwinds. The community is actively debating the potential for a strategic partnership with POSCO and the impact of the domestic transformer supply crunch on the company's long-term growth outlook.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

DRTS is gaining significant market attention as investors position themselves ahead of multiple clinical trial updates, specifically focused on pivotal readouts and oral presentations regarding pancreatic and skin cancer therapies. The community is increasingly bullish, highlighting a strong institutional presence and the company's clean balance sheet as key reasons for the stock's recent price strength despite broader market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lipocine (NASDAQ:LPCN) Director Buys $81,200.00 in Stock

Lipocine Inc. (NASDAQ:LPCN - Get Free Report) Director John Higuchi bought 40,000 shares of the firm's stock in a transaction dated Tuesday, April 7th. The stock was purchased at an average cost of...

Mahesh Patel Purchases 25,000 Shares of Lipocine (NASDAQ:LPCN) Stock

Lipocine Inc. (NASDAQ:LPCN - Get Free Report) CEO Mahesh Patel purchased 25,000 shares of Lipocine stock in a transaction that occurred on Monday, April 6th. The shares were bought at an average cost...

What's Going On With Lipocine Stock On Monday?

Lipocine stock rebounds after a steep drop as LPCN 1154 misses the Phase 3 endpoint, with encouraging subgroup data.read more...

Insider Buying: Lipocine (NASDAQ:LPCN) CEO Purchases 25,000 Shares of Stock

Lipocine Inc. (NASDAQ:LPCN - Get Free Report) CEO Mahesh Patel purchased 25,000 shares of the company's stock in a transaction that occurred on Thursday, April 2nd. The shares were acquired at an average cost of $2.02 per share, with a total value of $50,500.00. Following the completion of the...

<ul class="summary-bullets"><li>While the trial failed its primary endpoint of significant reduction in depression severity, the drug was well tolerated and demonstrated a favorable safety profile, the company said.&nbsp;</li><li>Lipocine, however, said that it has identified signals in a post hoc analysis that could indicate a potential development path for LPCN 1154.</li><li>The company said it will preserve capital and engage with shareholders to evaluate all options available to the company going forward.</li></ul>Shares of Lipocine Inc. (LPCN) fell 78% on Thursday after the company said that its experimental drug LPCN 1154 did not bring about a significant reduction in the severity of postpartum depression in a trial.While the trial failed its primary endpoint of significant reduction in depression severity, the drug was well tolerated and demonstrated a favorable safety profile enough to support outpatient administration without the need for healthcare provider monitoring, the company said. No treatment-related severe or serious adverse events were reported and no cases of excessive sedation or loss of consciousness were observed, it added.<h2 class="st-heading-2">What’s Next For Lipocine?</h2>Lipocine, however, said that it has identified signals in a post hoc analysis that could indicate a potential development path for LPCN 1154. The company has applied for breakthrough therapy and fast track designations for LPCN 1154 in patients with postpartum depression based on the post hoc analysis results, the company said.While it waits for the FDA to get back, the company said it will preserve capital and engage with shareholders to evaluate all options available to the company going forward, including continued development of LPCN 1154, development of other product candidates, strategic transactions, partnerships, and other opportunities, it said.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around LPCN rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.A Stocktwits user drew focus to the company’s remaining pipeline, which includes experimental drugs for the treatment of non-alcoholic steatohepatitis, for the management of symptoms associated with cirrhosis and another for the prevention of recurrent preterm birth.<stembedurl>https://www.stocktwits.com/Boknow/message/649308142</stembedurl>Another user expressed hopes for a minor recovery after the crash. &nbsp;<stembedurl>https://www.stocktwits.com/Ruttobillions/message/649292640</stembedurl><a href="https://stocktwits.com/symbol/LPCN">LPCN stock</a> has dropped 37% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sgml-stock-soars-on-100-m-bank-guarantee-retail-says-one-last-hurdle-is-behind/cZ7xCWQRI8Z">SGML Stock Soars On $100M Bank Guarantee, Retail Says 'One Last Hurdle' Is Behind</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Lipocine is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

LPCN Stock Crashes 78%— Here’s Why 

Lipocine said that its experimental drug LPCN 1154 did not bring about a significant reduction in the severity of postpartum depression in a trial.

Equity

Lipocine said that its experimental drug LPCN 1154 did not bring about a significant reduction in the severity of postpartum depression in a trial.


Lipocine Stock Tanks 78% After Phase 3 Oral Brexanolone Trial Failed To Meet Primary Endpoint

(RTTNews) - Shares of Lipocine Inc. (LPCN) are falling about 78 percent on Thursday morning trading following the announcement of topline results from its Phase 3 placebo-controlled trial, which failed to meet the primary endpoint. The trial evaluated LPCN 1154 or oral brexanolon...

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with...

Lipocine (NASDAQ:LPCN) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised Lipocine from a "sell" rating to a "hold" rating in a report on Sunday...

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 PR Newswire SALT LAKE CITY, March 10...

Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?

Lipocine (LPCN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

Current Price	$2.43
Prev Close	$2.56
Open	$2.51
Dividend Yield	0.00%
50-Day Moving Average	$7.03
Beta	0.65
Avg. Volume	106,231.57
PE Ratio	-1.38

52-Week High	$12.37
52-Week Low	$1.81
Market Capitalization	$17.74M
EPS (Annual)	-$1.77
Price to Book	1.03
Revenue Per Employee	$141,191.21

LPCN
Lipocine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LPCN News

LPCNLipocine Inc